{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-24-033629","form_type":"8-K","ticker":"LNTH","cik":"0001521036","company_name":"Lantheus Holdings, Inc.","filed_at":"2024-07-31T23:59:59+00:00","discovered_at":"2026-05-14T18:03:13.358543+00:00","generated_at":"2026-05-31T14:21:43.048969+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Lantheus Q2 revenue up 22.5% to $394.1M, adjusted EPS $1.80; lowers FY 2024 adjusted EPS guidance to $6.60-$6.70","bullets":["Revenue $394.1M (+22.5% YoY), driven by PYLARIFY sales $273.3M (+29.8%) and DEFINITY $78.1M (+10.7%).","GAAP diluted EPS $0.88 (vs $1.33); adjusted diluted EPS $1.80 (vs $1.54), +16.4%.","Acquired NAV-4694 (Alzheimer's), global rights to RM2 theranostic pair (prostate/breast), and two preclinical assets from Radiopharm Theranostics.","FY 2024 revenue guidance reaffirmed $1.50-1.52B; adjusted EPS guidance lowered to $6.60-6.70 from $7.00-7.20 due to BD investments.","CMS proposed OPPS rule improves separate payment for diagnostic radiopharmaceuticals like PYLARIFY in hospital outpatient setting."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-24-033629","json":"https://secwatch.observer/filing/0001628280-24-033629.json","markdown":"https://secwatch.observer/filing/0001628280-24-033629.md","text":"https://secwatch.observer/filing/0001628280-24-033629.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1521036/000162828024033629/0001628280-24-033629-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1521036/000162828024033629/lnth-20240731.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T14:21:43.048969+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}